Elsevier

Toxicology

Volume 97, Issues 1–3, 31 March 1995, Pages 23-38
Toxicology

Special paper
Mobilization of heavy metals by newer, therapeutically useful chelating agents

https://doi.org/10.1016/0300-483X(95)02965-BGet rights and content

Abstract

Four chelating agents that have been used most commonly for the treatment of humans intoxicated with lead, mercury, arsenic or other heavy metals and metalloids are reviewed as to their advantages, disadvantages, metabolism and specificity. Of these, CaNa2EDTA and dimercaprol (British anti-lewisite, BAL) are becoming outmoded and can be expected to be replaced by meso-2,3-dimercaptosuccinic acid (DMSA, succimer) for treatment of lead intoxication and by the sodium salt of 2,3-dimercapto-1-propanesulfonic acid (DMPS, DimavalR) for treating lead, mercury or arsenic intoxication. Meso-2,3-DMSA and DMPS are biotransformed differently in humans. More than 90% of the DMSA excreted in the urine is found in the form of a mixed disulflde in which each of the sulfur atoms of DMSA is in disulfide linkage with an l-cysteine molecule. After DMPS administration, however, acyclic and cyclic disulfides of DMPS are found in the urine. The Dimaval-mercury challenge test holds great promise as a diagnostic test for mercury exposure, especially for low level mercurialism. Urinary mercury after Dimaval challenge may be a better biomarker of low level mercurialism than unchallenged urinary mercury excretion.

References (62)

  • B. Tamboline et al.

    Radioactive compounds excreted by rats treated with 35S-labelled. British anti-lewisite; Preliminary studies

    Biochem. J.

    (1955)
  • C.R. Angle

    Childhood lead poisoning and its treatment

    Annu. Rev. Pharmacol. Toxicol.

    (1993)
  • H.V. Aposhian

    DMSA and DMPS-water soluble antidotes for heavy metal poisoning

    Annu. Rev. Pharmacol. Toxicol.

    (1983)
  • H.V. Aposhian et al.

    Urinary excretion of meso-dimercaptosuccinic acid in human subjects

    Clin. Pharmacol. Therap.

    (1989)
  • H.V. Aposhian et al.

    Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent

    Annu. Rev. Pharmacol. Toxicol.

    (1990)
  • H.V. Aposhian et al.

    Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with dental amalgam score

    FASEB. J.

    (1992)
  • H.V. Aposhian et al.

    Human studies with the chelating agents, DMPS and DMSA

    Clin. Toxicol.

    (1992)
  • J. Bankowska et al.

    Retention of lead in the rat

    Arch. Environ. Contain. Toxicol.

    (1985)
  • M. Berlin et al.

    Accelerated uptake of mercury by brain caused by 2,3-dimercaptopropanol (BAL) after injection into the mouse of methylmercuric compound

    Acta Pharmacol. Toxicol.

    (1965)
  • R.E. Bluhm et al.

    Elemental mercury vapour toxicity, treatment, and prognosis after acute, intensive exposure in choralkali plant workers: Part I: History, neuropsychological findings and chelator effects

    Human Exp. Toxicol.

    (1992)
  • J.R. Campbell et al.

    The therapeutic use of 2,3-dimercaptopropane-1-sulfonate in two cases of inorganic mercury poisoning

    JAMA

    (1986)
  • M.G. Cherian et al.

    Estimation of mercury burdens in rats by chelation with dimercaptopropane sulfonate

    J. Pharmacol. Exp. Therap.

    (1988)
  • J.J. Chisolm et al.

    Use of 2,3-dimercaptopropane-1-sulfonate in treatment of lead poisoning in children

    J. Pharmacol. Exp. Therap.

    (1985)
  • J.J. Chisolm

    Mobilization of lead by calcium disodium edetate; a reappraisal (editorial)

    Am. J. Dis. Child.

    (1987)
  • T.W. Clarkson et al.

    Tests of efficacy of antidotes for removal of methyl mercury in human poisoning during the Iraq outbreak

    J. Pharmacol. Exp. Therap.

    (1981)
  • T.W. Clarkson et al.

    The prediction of intake of mercury vapor from amalgams

  • T.W. Clarkson

    Mercury — an element of mystery

    N. Engl. J. Med.

    (1990)
  • D.A. Cory-Slechta et al.

    Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy

    J. Pharmacol. Exp. Therap.

    (1987)
  • D.A. Cory-Slechta

    Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy

    J. Pharmacol. Exp. Therap.

    (1988)
  • J. Damrau

    Zur Therapie quecksilberinduzierter Organschäden

    Z. Gesamte Inn. Med.

    (1990)
  • G.S. Ding et al.

    Antidotal effects of dimercaptosuccinic acid

    J. Appl. Toxicol.

    (1991)
  • Cited by (0)

    View full text